Abernethy, Shuren, issue statement on FDA breast implant labelling guidance

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

In light of new FDA labeling recommendations for saline and silicone gel-filled breast implants, FDA officials Amy Abernethy and Jeffrey E. Shuren issued a statement outlining the agency’s recommendations for manufacturers.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

The European Society For Medical Oncology has formally weighed in on a question that U.S. medical groups have been chipping away at as well: How can we guarantee safe and effective use of artificial intelligence in oncology?

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login